Assessing the Viability of FDA’s Biosimilars Pathway
Couldn’t attend the event? Check out some of our speakers’ slide presentations!
Description
The 2010 passage of the Biologics Price Competition and Innovation Act was intended to create a pathway for the approval of biosimilar drugs, to bring to market less expensive versions of innovators’ biologic therapeutics in the same way the Hatch-Waxman Act has worked so well for FDA approval of generic small-molecule drugs. But the Act has been mired in a host of statutory, regulatory, and scientific complication and delays, and five years later, the FDA has approved just one biosimilar product.
This panel brought together experts from legal practice, industry, and academia to discuss each of these issues and to recommend ways in which the agency and industry can move forward.
Panelists
Learn More
Couldn’t attend the event? Check out some of our speakers’ slide presentations!
- Donald R. Ware, “Assessing the Viability of FDA’s Biosimilars Pathway”
This event was free and open to the public.
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.